Call us on 03 9898 6353

Category: Uncategorized

Approval of Orphan Drug Designation application

February 11, 2015
Plunkett Consulting, on behalf of our international client, has been assigned Orphan Drug Designation by the Therapeutic Goods Administration (TGA) for a new treatment malignant pleural mesothelioma currently in development. As part of  this collaboration, Plunkett Consulting has prepared and submitted a comprehensive Orphan Drug Designation application to the TGA, that provides a detailed overview